openPR Logo
Press release

Data from microarrays co-developed by OGT to be presented at ECC 2011

07-06-2011 08:26 AM CET | Science & Education

Press release from: Oxford Gene Technology - OGT

/ PR Agency: Alto Marketing
Talk will deliver new insights into the association of copy number variation and a range of developmental disorders

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July). Professor Joris Vermeesch, Head of the Laboratory for Cytogenetics and Genome Research at Katholieke Universiteit Leuven will present data obtained using aCGH microarrays co-developed with OGT. The presentation entitled “About inherited pathogenic and de novo benign CNVs”, will discuss the use of aCGH to deliver new insights into the association between copy number variation and a range of developmental disorders. Some of the data to be presented was obtained using a unique custom microarray that combines OGT’s CytoSure™ ISCA 8x60k and CytoSure Syndrome Plus v2 2x105k arrays into a 4x180k format. This design facilitates data sharing between ISCA consortium members and the comparison of new data with legacy data. Additional data generated using this array was presented at the recent European Society of Human Genetics (ESHG) Meeting in Amsterdam by Paul Brady, a PhD student in Professor Vermeesch’s lab. This presentation entitled “The use of array CGH for prenatal diagnosis of foetuses with congenital malformations detected by ultrasound” is available to download on the OGT website.

The new combined array is just one tool developed as part of the successful ongoing relationship between OGT and the Katholieke Universiteit Leuven. Researchers at the University have also recently utilised OGT CytoSure custom designed arrays, CytoSure DNA Labelling Kits and class-leading CytoSure Interpret Software to identify genomic imbalances associated with congenital diaphragmatic hernia (CDH), with the work subsequently published in the journal Prenatal Diagnosis. In addition, studies conducted at the University were instrumental in the development of the CytoSure Aneuploidy array, which allows simple, reliable and cost-effective detection of whole chromosomal imbalances in miscarriage samples. Such examples excellently illustrate how the collaborations formed between OGT and world-class academic institutes are leading to the development of superior tools for use in cytogenetic research. Professor Joris Vermeesch commented: “The complex nature of our work requires a high level of accuracy combined with in-built flexibility. Working with OGT provides both, allowing us to optimise our aCGH design and workflow to generate the best results possible from each individual study.”

Register now for OGT’s ECC workshop.

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Alto Marketing

Office 3 | Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL

OGT enquiries
Oxford Gene Technology - OGT
Stephen Archibald – Marketing Communications Manager
t: +44 (0)1865 856828
e: stephen.archibald@ogt.co.uk

Media enquiries
Alto Marketing Limited
Paul Avery – Science Writer
t: +44 (0)1489 557672
e: paulavery@alto-marketing.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Data from microarrays co-developed by OGT to be presented at ECC 2011 here

News-ID: 182309 • Views: 1200

More Releases from Oxford Gene Technology - OGT

OGT sequencing workshop at ESHG 2011 attracts over 130 delegates
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled “Adding value through analysis”, attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service. Built
OGT to develop tumour profiling assay to facilitate personalised cancer treatmen …
Company receives £1.16m award from the UK’s Technology Strategy Board Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced that it has received a funding award of £1.16 million from the UK government-backed Technology Strategy Board. As part of the project, OGT will develop a tumour profiling assay based on targeted panel enrichment and next generation sequencing (NGS). The new assay
OGT announces new targeted next generation sequencing service
Delivering discovery, not just data Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the release of its next generation targeted sequencing service. With an emphasis on flexibility, expert project design and advanced data analysis, the new offering takes advantage of OGT’s high-quality processes and in-house bioinformatics experience to provide the most complete targeted sequencing solution available. This includes whole exome
OGT to unveil sequencing offering at ESHG 2011
OGT’s “Adding value through analysis” workshop to showcase new services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a workshop at this year’s European Society of Human Genetics (ESHG) conference in Amsterdam. The workshop, entitled “Adding value through analysis”, will take place on Saturday the 28th of May and will reveal details of OGT’s new comprehensive targeted sequencing service. Hosted between

All 5 Releases


More Releases for CytoSure

OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid
OGT to Host Workshop at ICHG/ASHG 2011
Seminar will discuss how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will
OGT aids research into molecular genetic disease
Unique CytoSure™ Molecular Testing Arrays provide high throughput CNV detection for multiple disorders on a single chip Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a new range of CytoSure™ Molecular Testing Arrays and Panels. The new DNA microarrays utilise a unique collection of probes for detecting copy number variations (CNVs) within genes associated with a variety of disorders. Three
OGT sequencing workshop at ESHG 2011 attracts over 130 delegates
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled “Adding value through analysis”, attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service. Built
OGT to unveil sequencing offering at ESHG 2011
OGT’s “Adding value through analysis” workshop to showcase new services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a workshop at this year’s European Society of Human Genetics (ESHG) conference in Amsterdam. The workshop, entitled “Adding value through analysis”, will take place on Saturday the 28th of May and will reveal details of OGT’s new comprehensive targeted sequencing service. Hosted between
OGT to exhibit its biomarker and genomic services solutions at AACR 2011
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a booth and exhibit a poster at this year’s American Association for Cancer Research (AACR) meeting in Florida, USA (2nd to 6th of April, 2011). The AACR show and exhibition is an important international event discussing the latest developments in cancer research. OGT’s booth will be manned by Gareth Thomson (Director of